Sinocare presents integrated chronic disease management solutions at EASD 2026

Sinocare, a Chinese company, presented its integrated portfolio of chronic disease management solutions at the 62nd annual meeting of the European Association for the Study of Diabetes (EASD 2026) in Milan. The solutions are tailored for home care, pharmacies, and hospitals, covering key stages from risk screening to daily monitoring and clinical testing.

For home care, Sinocare featured the Safe AQ max II blood glucose monitoring system, which provides results within five seconds and supports Bluetooth data synchronization. The KUG-11 meter, a 3-in-1 device for glucose, uric acid, and ketone testing, and the GV-100 system for veterinary blood glucose monitoring were also displayed.

At the pharmacy level, the company introduced the iCARE-1300 portable analyzer, capable of automated testing of nearly 100 parameters, including blood glucose and lipid profiles, with results in 3-15 minutes. For hospitals, Sinocare presented the AGEscan fluorescence detector for non-invasive detection of advanced glycation end products (AGEs) to aid early risk detection. The Safe AQ 8000 Hospital Blood Glucose Smart Management System was also highlighted for integrating blood glucose and CGM data with hospital information systems.

These solutions demonstrate Sinocare's approach to connecting screening, monitoring, and long-term management across different healthcare settings. The company intends to continue advancing biosensor technology and integrated health solutions to support more accessible and connected chronic disease management worldwide.